HOWLWerewolf Therapeutics, Inc.

$35M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$16M

Net Income

-$16M

EPS (Diluted)

$-0.36

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$80M

Total Liabilities

$50M

Stockholders' Equity

$30M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$16M	-$17M	+8.2%
Net Income	-$16M	-$17M	+1.8%

HOWL Q3 2025 Earnings — Werewolf Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena